Objective: To compare the antitumor effect of abiraterone (AA) followed by docetaxel-prednisone (DP) or vice versa in metastatic castration-resistant prostate cancer (mCRPC) patients, and explored factors that might predict combined PSA-PFS, combined rPFS and OS.
Conclusion:
In this study, we did not observe differences in clinical outcomes based on alternative sequencing of AA and DP in mCRPC patients. The ability to tolerate side effects and patient preference may be used to determine the treatment sequencing. In addition, high pretreatment SII level is a negative independent prognosticator of survival outcomes in mCRPC with sequential therapy using DP followed by AA or vice versa, which might guide clinicians select the best treatment.
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| INTRODUCTION
Since docetaxel had been proven to improve overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC), several therapeutic strategies have also been approved for the treatment of mCRPC at present. [1] [2] [3] [4] [5] [6] Despite these advances, a number of clinical issues remain unresolved, including the proper sequential use of drugs and drug cross-resistance.
Retrospective studies of sequential use of abiraterone (AA) and docetaxel-prednisone (DP) suggested that the second agent used showed diminished efficacy after progression on the first drug regardless of AA followed by DP or vice versa. Cross-resistant mechanisms between AA and DP might lead to impair the therapeutic efficacy. There are many mechanisms of resistance which have been identified. [7] [8] [9] [10] However, neither of these studies answered the question of optimal sequencing of AA and DP with respect to long-term clinical outcomes. To date, no prospective studies have been conducted to explore the optimal sequential use of these drugs. In addition, owing to the abundance of treatment selections of mCRPC, how to predict the prognosis of patients with sequential use of AA and DP remained to be solved.
It is clear that systemic inflammatory response is one of the vital determinants of cancer progression. However, it is increasingly recognized that infiltrating inflammatory cells in the immune system are generic constituents of tumors that have opposing functions, as both tumor antagonists and promoters. Previous studies have reported that circulating immune-inflammatory cells such as neutrophils, lymphocytes, and platelets could contribute to cancer cell proliferation, invasion, and migration. [11] [12] [13] [14] [15] In consideration of these evidences, several inflammation and immune-based prognostic indices have been developed to predict cancer recurrence and mortality, such as neutrophils-lymphocyte ratio (NLR) 16 and prognostic nutrition index (PNI) 17 Recently, a novel systemic immune-inflammation index named SII, which can comprehensively reflect the balance of host immune and inflammatory status, has emerged and been proved as a promising prognostic indicator in gastric cancer, hepatocellular carcinoma, and prostate cancer (PCa). [18] [19] [20] However, the value of SII in sequential treatment choice of mCRPC has remained to be investigated. Owing to the approval of immunity therapy in the treatment of mCRPC, it is increasingly to note that if combining other standard treatment with immunity therapy would assist to improve the prognosis of mCRPC patients. 21, 22 However, there is lack of biomarkers to predict who would get the best benefit from immunity therapy. High SII value, which can comprehensively reflect the defect of host tumor immune, might indicate poor response to AA or DP rather than immunity therapy.
In this study, we investigated the antitumor effect of AA followed by DP or vice versa in mCRPC patients, and explored factors that might affect combined PFS and OS. The study endpoints were combined PSA progressive free survival (PSA-PFS), combined radiographic progressive free survival (rPFS) and overall survival (OS). Combined PSA-PFS and combined rPFS were measured from the start of the first mCRPC therapy (ie, DP or AA) until the time of PSA or radiographic progression, respectively on the subsequent alternative therapy (combined PFS = PFS1 + PFS2, where PFS1 and PFS2 are the progression-free intervals on the first and second agents, respectively). PSA-PFS was according to PCWG2 criteria, 23 and radiographic progression was based on Response Evaluation Criteria in Solid Tumors (RECIST) 23 or two or more new bone lesions on bone scan or death, whichever occurred first.
| Statistical analysis
The optimal cut-off value for classifying SII and NLR as low or high for subsequent analysis, which was determined using ROC curve analysis,
was 200 and respectively. The cutoff points to stratify PSA was using PSA ≥median to identify high PSA.
Frequencies and proportions were assessed for categorical variables, whereas means, medians, and ranges were computed for continuous variables. For categorical variables, Pearson's chi-squared test was used.
Correlations with combined PSA-PFS, and combined rPFS, and OS were assessed using Kaplan-Meier curves with log-rank statistics. Furthermore, uni-and multivariate Cox regression analyses were used to calculate their respective hazard ratios (HRs) and 95%CIs. Only factors significant in univariate analyses were included in the subsequent multivariate analyses.
A test result was considered as statistically significant for P < 0.05. We used SPSS version 21.0 for other key analyses.
3 | RESULTS
| Patients characteristics
At a median follow-up of 20.2 months, a total of 104 mCRPC patients met eligibility criteria between 2013 and 2017. The clinical and pathological data of all patients are listed in Table 1 . Forty-two were in the DP-to-AA group and 62 were in the AA-to-DP group. There was no significant heterogeneity between DP-to-AA group and AA-to-DP group in this study ( Baseline characteristics were shown in Table 2 , and generally similar between these two groups. Owing to these, we compared the clinical outcomes between AA-to-DP group and DP-to-AA group. There was no significant difference in combined PSA-PFS (AA-to-DP: 12. 6.0-8.8) (P < 0.001) in patients with baseline SII value <200 or ≥200, respectively ( Figure 2 ).
In the DP-AA group, the median OS, PSA-PFS, rPFS were 23.6 months (95%CI: 22. 11.4-11.6) (P < 0.001), 17.6 months (95%CI: 14.6-20.6) and 9.7 months (95%CI: 9.3-10.1) (P < 0.001) in patients with baseline SII value <200 or ≥200 respectively ( Figure 2 ).
In univariate analysis, four variables were significant determinants of the combined PSA-PFS, combined rPFS and OS (Table 3) . In multivariate analysis, low SII level (HR, 8.7; P < 0.001) was an independent predictor of combined PSA-PFS, along with ECOG PS>1
(HR, 11.3; P = 0.002), but NLR was not. As to rPFS, multivariable analysis also demonstrated that low SII (HR, 3.7; P = 0.003) was an independent predictor of rPFS, along with ECOG PS>1 (HR, 4; P = 0.006), but NLR was not. In multivariate analysis, low SII level (HR, 13.2; P < 0.001), remained significant predictors of OS, while NLR was not (Table 4) .
| DISCUSSION
In this retrospective study, we compared the combined PFS and OS between two alternative treatment sequences of DP and AA in mCRPC patients. We did not observe differences with respect to any of the endpoints studied based on alternative sequencing of AA and DP in mCRPC patients. As we know, this study was the first study which compared the clinical outcomes between two alternative treatment sequences of DP and AA in Asian mCRPC patients. At present, in China, AA and DP were main treatment choice for mCRPC and enzalutamide or cabazitaxel et al have not been approved for the treatment in Chinese mCRPC patients. Owing to these, the comparison of clinical outcomes between AA-to-DP group and DP-to-AA group in this study seemed to not be interfered by these treatment choices. Further prospective studies would be conducted to confirm this conclusion.
Our results were consistent with a similar study by Maughan et al. 24 In this retrospective analysis of treatment sequence comparing DP-to-AA or the alternate sequence, 26 mCRPC patients received DP-to-AA compared with 32 patients who received AA-to-DP.
Although patients in the AA-to-DP group had more Gleason 8-10
tumors, greater bone metastatic burden, and higher median PSA than those in the DP-to-AA group, they showed no significant difference in median combined PFS and OS between these groups. It is noted that patients in that analysis could have received intervening therapy after DP and AA treatment, while they did not show these data, which might lead to the unreliability of conclusion. In our study, we compared the baseline characteristics, and they were generally similar between these two groups. Moreover, we excluded the patients who received intervening therapy before or after DP and AA treatment, which further support the conclusions. 
25-27
Neutrophils play a crucial role in tumor microenvironment to promote cancer progression and metastasis via secreting cytokines and chemokines. 28, 29 Lymphocytes play a significant role in tumor immunity by inducing cytotoxic cell death and inhibiting tumor proliferation and migration, 12 which lead to the host immune response to malignancy. 30 In consideration of these factors, a novel immune-inflammation-based prognostic score (SII) was constructed based on lymphocyte, neutrophil, and platelet counts and shown to be an independent predictor of survival for patients with cancer. 18, 19 In our study, we also found baseline high SII level was also associated with poorer clinical outcome in mCRPC patients receiving regardless of AA-to-DP or DP-to-AA, which might guide clinicians select the best treatment for mCRPC patients. Moreover, several studies found there is a potential association of the SII with peripheral blood CTCs mediated to tumor metastasis and progression, which would provide a
FIGURE 2
The comparison of clinical outcomes between patients with baseline SII value <200 and ≥200 in AA-to-DP group and DP-to-AA group The duration of response to ADT (<12 months vs ≥12 months) It is interesting to note that baseline high SII level was also associated with poorer clinical outcome in mCRPC patients receiving regardless of AA-to-DP or DP-to-AA, which is consistent with previous reports suggesting the prognostic value of SII in cancer. 18, 19 In addition, SII has shown to be more accurate than NLR in predicting the prognosis of mCRPC patients, which was consistent with previous studies in hepatocellular carcinoma 19 and small-cell lung cancer. 32 We assumed SII additionally reflected the function of platelet compared with NLR, thereby it was more accurate than NLR in predicting the prognosis of mCRPC patients. SII is a convenient, easily obtained, lowcost, and non-invasive biomarker that is a complement to conventional prognostic models as a prognostic predictor for PCa patients. Patients with a high SII may be more suitable candidates for immunotherapy rather than a sequential treatment with DP and AA.
Because the most widely used routine prognostic assessment of mCRPC currently still relies on traditional clinicopathological prognostic variables including the type and duration of prior therapy, LDH and NLR, 20, 33 recent advance in the identification of molecular and genetic alterations in mCRPC has been made. [34] [35] [36] [37] In spite of these biomarkers enhancing the predictive accuracy of prognostic model, the high costs of analysis, the time-consuming preparation and the lack of evidence together prevent them into clinical practice. In the present study, we showed that high SII level was associated with poorer clinical outcome in mCRPC patients receiving regardless of AA-to-DP or DP-to-AA. Owing to the plentiful treatment choices in mCRPC and high cost of treatment, detailed understanding of individual risk prognostic factor will impart benefits for clinical outcome and individual patient treatment choices, such as immunotherapy or radiotherapy.
Furthermore, SII could represent a novel predictive marker of clinical outcome to other treatments such as immunotherapy, radiotherapy in
PCa, and should be tested in these clinical situations.
This study has some limitations. First, it was a single-center, retrospective study with a relatively small sample size. The number of patients was small and imbalanced between groups. Second, radiographic assessment should be performed every 3 months as the reference; however, this being a retrospective analysis, patients whose images were not assessed every 3 months were also included. In addition, to prove the prognostic factor of SII, further large-scale population-based prospective studies will be needed to conduct to fully consolidate the results. 
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